Eurofins Strengthens Its Comprehensive Food Testing Offering in Japan With the Purchase of QSAI Analysis and Research Center Co.,Limited.

Eurofins Scientific, the worldwide leader in food testing along with a global scientific leader in bioanalytical testing, announces the signing of the agreement to get a majority stake in QSAI Analysis and Research Center Co.,Limited. (“QARC”).

QARC began in 2013 like a spin-removed from QSAI’s R&D center and it has been consistently developing pesticide screening along with other food testing abilities for 25 years, serving a comprehensive subscriber base within the food, wholesale and retail industries in addition to institutions and governments. QARC is recognised among the leading private pesticide testing laboratories in Japan, providing the largest portfolio well over 800 pesticide screening tests covering a number of complex food matrices. QARC employs 80 individuals its laboratories in Fukuoka and Nagoya and it is accredited against ISO/IEC 17025 and also the Secretary of state for Health, Work and Welfare (MHLW).

The purchase of QARC will complement the Eurofins network’s extensive food testing abilities with pesticide, veterinary drug, foreign object and physical testing services. The purchase will further strengthen Eurofins’ presence in Japan and also the Eurofins network’s offering to customers importing and conveying foods.

About Eurofins – the worldwide leader in bio-analysis

Eurofins is Testing for Existence. Eurofins may be the world leader in food, atmosphere, pharmaceutical and cosmetic product testing, as well as in discovery pharmacology, forensics, advanced material sciences and agroscience Contract Research services. Eurofins is another market leader in a few testing and laboratory services for genomics, as well as in the support of studies, plus BioPharma Contract Development and Manufacturing. The Audience also offers a quickly developing presence in highly specialised and molecular clinical diagnostic testing as well as in-vitro diagnostic products.

With more than 61,000 staff across a decentralised and entrepreneurial network of 940 laboratories in 59 countries, Eurofins provides a portfolio well over 200,000 analytical techniques to assess the safety, identity, composition, authenticity, origin, traceability and wholesomeness of an array of products, in addition to supplying innovative clinical diagnostic testing services as well as in-vitro diagnostic products.

The Group’s objective would be to provide its customers rich in-quality services, innovative solutions and accurate results promptly. Eurofins is ideally positioned to aid its clients’ more and more stringent quality and safety standards and also the growing demands of regulatory government bodies along with the needs of healthcare practitioners all over the world.

In 2020 and 2021, Eurofins reacted rapidly to satisfy the worldwide challenge of COVID-19, by creating the ability to help over 20 million patients monthly and also require been influenced by the pandemic with this testing products and our services and directly supporting medical professionals focusing on the leading line to battle herpes. The Audience has built prevalent PCR testing abilities and it has transported out over 40 million tests in the own laboratories, is supporting the introduction of numerous vaccines and it has established its [email protected]™ testing, monitoring and talking to programmes to assist ensure safer environments, travel and occasions during COVID-19.

Eurofins is continuing to grow very strongly since its beginning and it is technique is to carry on expanding its technology portfolio and it is geographic achieve. Through R&D and acquisitions, the audience draws around the latest developments in the area of biotechnology and analytical chemistry to provide its clients unique analytical solutions.

Shares in Eurofins Scientific are on the Euronext Paris Stock Market (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).

Until it’s been legitimately published broadly by Eurofins through approved distribution channels, this document contains inside information with regards to Regulation (EU) 596/2014 from the European Parliament as well as the Council of 16 April 2014 on market abuse, as amended.

Important disclaimer:

This pr release contains forward-searching statements and estimates which involve risks and uncertainties. The forward-searching statements and estimates contained herein represent the judgment of Eurofins Scientific’s management by the date of the release. These forward-searching statements aren’t guarantees for future performance, and also the forward-searching occasions discussed within this release might not occur. Eurofins Scientific disclaims any intent or obligation to update these forward-searching statements and estimates. All statements and estimates are created in line with the information open to their management by the date of publication, but no guarantees can be created regarding their completeness or validity.